
A PRELIMINARY microRNA ANALYSIS OF NON SYNDROMIC
THORACIC AORTIC ANEURYSMS Patuzzo C1,*, Pasquali A1, Malerba G1, Trabetti E1,
Pignatti PF1, Tessari M2, Faggian G2 *Corresponding Author: Dr. Cristina Patuzzo, Department of Life and Reproduction Sciences, University
of Verona, Strada Le Grazie 8, 37134,Verona, Italy; Tel.: +39-45-802-7207; Fax: +39-45-802-7180; E-mail:
cristina.patuzzo@univr.it page: 51
|
DISCUSSION
In this study, RNA pools obtained from ascending
thoracic aortic wall fragments of patients
affected by TAA were competitively hybridized
with control pools on microarrays spotted with oligonucleotides
putatively recognizing 728 miRNAs.
Ninety-nine miRNAs were differentially expressed.
The miRNA sequences listed were matched to gene
sequences and linked to annotated pathways of gene
expression. The most enriched pathways, which included
a high number of putative target genes of differentially
expressed miRNAs, were focal adhesion
and adherens junction.
The most interesting result concerned the 11 upregulated
miRNAs, both in male and female TAAs,
which putatively matched 61 genes related to the
adhesion processes. This indicates a significant
modulation, i.e., repression, of the focal adhesion
pathway. The adherens junction pathway, on the basis
of the putative targeting by miRNAs, resulted
as repressed and stimulated in 26 and 15 genes, respectively.
These opposite signals could be a manifestation
of the cellular cohesion impairment and of
the attempt to reconstitute the integrity of the aortic
wall during the development of TAA.
No sex differences were observed in the present
study, as miRNAs differentially expressed in
males versus females targeted genes belonging to
the same general pathways. Some of the differentially
expressed miRNAs identified in this study are
in agreement with the literature, as reported below.
Down-Regulated microRNAs. Phenotypic abnormalities
of vascular smooth muscle cells (VSMCs)
and cardiomyocytes have been observed in MIR-133
knockout mice [15]. MIR-145 is decreased in aortas
from patients with an aneurysm and was suggested as
a potential biomarker for vascular diseases [16].
Up-Regulated microRNAs. MIR-126, the
most up-regulated miRNA in this study, has been
implicated in the maintenance of vascular integrity
[17] and in vascular cell adhesion molecule expression
[18]. MIR-29B-mediated down-regulation of ECM proteins predisposes the aorta to the formation
of aneurysms [19]. MIR-21 has been investigated
extensively in various tissues and it has been
found to promote vascular smooth muscle cell
(VSMC) proliferation [16]. Knockdown of MIR-
221 and MIR-222 by antisense oligonucleotide
miRNA depletion has been foun to reduce VSMCs
proliferation in response to vascular injury, and both
miRNAs are strongly elevated in vivo in VSMCs
following vessel injury [16]. MIR-146, MIR-24 and
MIR-26 have been implicated in VSMCs proliferation
and contraction [16]. MIR-15A, MIR-16, MIR-
16-1, MIR-16-2, and MIR-195 belong to a family of
miRNAs (the miR-15 family) consistently found to
be up-regulated in cardiovascular diseases [5].
In conclusion, and in concordance with other
investigators [20], our study indicates that the
weakness of the ascending aortic tissue in TAA is
linked with a perturbation of cell adhesion and cell
interaction gene expression pathways. MicroRNAs
probably act as regulators, possibly driving, or at
least influencing, the development of the disease.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|